Checkpoint inhibitors have transformed cancer therapy by enhancing immune responses against tumors. However, their effectiveness is limited, as many patients do not respond due to the absence of a pre-existing immunity against the cancer cells. Addressing this gap requires new immunotherapies that can promote cancer-cell antigen recognition and engage multiple immune pathways to effectively reprogram the tumor microenvironment and stimulate a robust antitumor response.